Primary chemotherapy with temozolomide vs. radiotherapy in patients with low grade gliomas after stratification for genetic 1p loss: a phase III study

Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. At the time of writing this protocol it was not known whether radiation therapy was more effective than temozolomide in treating gliomas. The purpose if this randomized phase III trial was to study radiation therapy to see how well it works compared to temozolomide in treating patients with gliomas.

Primary Sponsor

EORTC

Collaborating Groups

TROG Cancer Research, CCTG, MRC-NCRI, Brain Tumour Group

Participating Centres

Current Accrual

Closing Date of Accrual

March 2010

Trial Chairperson

Dr Gail Ryan, Peter MacCallum Cancer Centre, VIC

Clinical Trial Registration

Related Post

August 2, 2022

Celebrating and bringing radiation medicine research to the forefront at our 2022 ASM

After a hiatus from in-person events due to COVID-19

February 28, 2022

Cancer trial participant hoping to help

The RAVES trial treating prostate cancer Participating in a